News + Filings Transactions
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
Lundberg Sven Ante
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
06/02/2023 |
4
| Lundberg Sven Ante (Director) has filed a Form 4 on Vor Biopharma Inc.
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
11/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/23/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
08/22/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/13/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/16/2022 |
4
| Lundberg Sven Ante (Director) has filed a Form 4 on Vor Biopharma Inc.
Txns:
| Granted 16,911 options to buy
@ $4.26, valued at
$72k
|
|
02/02/2022 |
4
| Lundberg Sven Ante (President, CEO & PFO) has filed a Form 4 on Merus N.V.
Txns:
| Granted 295,000 options to buy
@ $24.61, valued at
$7.3M
|
|
08/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/29/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/18/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/09/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/06/2020 |
4
| Lundberg Sven Ante (President, CEO & PFO) has filed a Form 4 on Merus N.V.
Txns:
| Granted 414,917 options to buy
@ $13.52, valued at
$5.6M
|
|
02/10/2017 |
4
| Lundberg Sven Ante (Chief Scientific Officer) has filed a Form 4 on CRISPR Therapeutics AG
Txns:
| Converted 55,217 shares
@ $0 Bought 400 shares
@ $14, valued at
$5.6k
Converted 55,217 options to buy
@ $0 |
|
|
|